Damora Therapeutics (DMRA) investor relations material

Strategic vision and leadership

• Focused on redefining care for blood disorders, particularly myeloproliferative neoplasms (MPNs) driven by CALR mutations.

• Founded by Fairmount Funds Management, with experienced R&D and commercial leadership.

• Supported by premier investors and listed on NASDAQ.

Pipeline and clinical development

• Lead asset DMR-001 is a next-generation anti-mutCALR antibody with superior potency and exposure, targeting both Type 1 and Type 2 mutations.

• DMR-001 is designed for convenient, infrequent subcutaneous dosing via autoinjector, aiming for best-in-class efficacy and patient experience.

• Additional assets DMR-002 (Fc-enhanced) and DMR-003 (T-cell engager) are advancing toward regulatory submissions in 2026 and 2027.

• Phase 1/1b CLARITY-101 trial for DMR-001 initiated in Q3 2026, with two clinical proof-of-concept readouts expected beginning mid-2027.

Market opportunity and competitive positioning

• Estimated US addressable market for mutCALR-driven MPNs exceeds $5B, with ~42,000 patients eligible for targeted therapy.

• DMR-001 is positioned to capture significant market share due to its convenient SC dosing and potential for first-to-market status.

• Current standard of care leaves significant unmet need, with many patients resistant or intolerant to existing therapies.